Published in Br J Psychiatry on May 01, 2011
Treatment of Psychosis and Agitation in Alzheimer's Disease | NCT02129348
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Treatment for mild cognitive impairment: systematic review. Br J Psychiatry (2013) 1.58
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci (2014) 1.18
Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. J Psychiatry Neurosci (2012) 1.17
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci (2014) 0.98
Food for thought: the role of appetitive peptides in age-related cognitive decline. Ageing Res Rev (2013) 0.97
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther (2013) 0.94
Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci (2012) 0.93
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One (2012) 0.93
More good news about the magic ion: lithium may prevent dementia. Br J Psychiatry (2011) 0.93
Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther (2013) 0.92
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci (2011) 0.91
GSK3 as a Sensor Determining Cell Fate in the Brain. Front Mol Neurosci (2012) 0.90
Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord (2013) 0.89
Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discov (2011) 0.87
Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain Res Bull (2011) 0.86
Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. BMJ Open (2013) 0.85
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. Theranostics (2016) 0.84
New treatment strategies for Alzheimer's disease: is there a hope? Indian J Med Res (2013) 0.82
GSK-3β and memory formation. Front Mol Neurosci (2012) 0.82
A randomized clinical trial of lithium in multiple system atrophy. J Neurol (2012) 0.82
Lithium and autophagy. ACS Chem Neurosci (2014) 0.82
Using lithium as a neuroprotective agent in patients with cancer. BMC Med (2012) 0.82
Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. World J Psychiatry (2011) 0.81
Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disord (2014) 0.81
Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study. ACS Chem Neurosci (2014) 0.81
Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. Korean J Physiol Pharmacol (2014) 0.81
Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment. Curr Genomics (2013) 0.81
Potential application of lithium in Parkinson's and other neurodegenerative diseases. Front Neurosci (2015) 0.81
A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord (2015) 0.80
Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. J Psychiatr Res (2014) 0.80
Mood disorders in the elderly: prevalence, functional impact, and management challenges. Neuropsychiatr Dis Treat (2016) 0.79
Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One (2013) 0.79
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. PLoS One (2013) 0.79
Drugs for Alzheimer's disease. Br J Clin Pharmacol (2012) 0.79
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf (2015) 0.78
History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry (2017) 0.77
Cognitive Consequences of Aging with HIV: Implications for Neuroplasticity and Rehabilitation. Top Geriatr Rehabil (2014) 0.77
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis (2016) 0.76
Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. J Mol Psychiatry (2016) 0.76
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification. Neural Regen Res (2016) 0.76
Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus. J Neural Transm (Vienna) (2014) 0.76
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat (2016) 0.75
Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series. Alzheimer Dis Assoc Disord (2016) 0.75
Chronic lithium feeding reduces upregulated brain arachidonic acid metabolism in HIV-1 transgenic rat. J Neuroimmune Pharmacol (2012) 0.75
An observational study of 110 elderly lithium-treated patients followed up for 6 years with particular reference to renal function. Int J Bipolar Disord (2017) 0.75
Enhanced Molecular Aging in Late-Life Depression: the Senescent-Associated Secretory Phenotype. Am J Geriatr Psychiatry (2016) 0.75
Understanding the neuroprotective mechanisms of lithium may have clinical significance. Br J Psychiatry (2011) 0.75
Strategies for dementia prevention: latest evidence and implications. Ther Adv Chronic Dis (2017) 0.75
Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line. Eur J Drug Metab Pharmacokinet (2017) 0.75
BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Transl Psychiatry (2017) 0.75
Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2015) 0.75
Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry (2014) 2.13
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. Neurobiol Aging (2009) 1.46
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. Int J Psychophysiol (2002) 1.17
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry (2005) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
The generators of slow potentials obtained during verbal, pictorial and spatial tasks. Int J Psychophysiol (2003) 1.16
Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci (2006) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Reduced cortical folding in schizophrenia: an MRI morphometric study. Am J Psychiatry (2003) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Voxel-based morphometry in Alzheimer's disease. Expert Rev Neurother (2008) 1.04
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry (2009) 1.04
Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry (2004) 1.00
Mortality from dementia in a community-dwelling Brazilian population. Int J Geriatr Psychiatry (2005) 0.99
Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res (2003) 0.99
Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 0.98
Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry (2010) 0.97
Mild cognitive impairment: cognitive screening or neuropsychological assessment? Rev Bras Psiquiatr (2008) 0.97
Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. J Int Neuropsychol Soc (2010) 0.96
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Alzheimer's disease. Subcell Biochem (2012) 0.95
Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med (2012) 0.93
Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry (2014) 0.93
Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett (2011) 0.93
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res (2012) 0.92
Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J Clin Psychiatry (2007) 0.90
CAMcog as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education. Int J Geriatr Psychiatry (2008) 0.89
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res (2010) 0.89
Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr (2010) 0.88
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol (2007) 0.88
Mild cognitive impairment. Part 1: clinical characteristics and predictors of dementia. Rev Bras Psiquiatr (2013) 0.87
Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res (2008) 0.86
Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids (2006) 0.86
Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology (Berl) (2008) 0.86
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Circulating Glial-derived neurotrophic factor is reduced in late-life depression. J Psychiatr Res (2011) 0.86
Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology (Berl) (2005) 0.85
Optimizing the CAMCOG test in the screening for mild cognitive impairment and incipient dementia: saving time with relevant domains. Int J Geriatr Psychiatry (2011) 0.84
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res (2004) 0.84
Complex slow potential generators in a simplified attention paradigm. Int J Psychophysiol (2005) 0.84
Effects of a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer's disease. Clinics (Sao Paulo) (2011) 0.84
Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology (2012) 0.84
Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.84
Loss of interest, depressed mood and impact on the quality of life: cross-sectional survey. BMC Public Health (2011) 0.83
Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.83
The Short Cognitive Performance Test (SKT): a preliminary study of its psychometric properties in Brazil. Int Psychogeriatr (2005) 0.83
Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukot Essent Fatty Acids (2008) 0.82
Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer's disease. PLoS One (2012) 0.82
Proteome analysis of human dorsolateral prefrontal cortex using shotgun mass spectrometry. J Sep Sci (2008) 0.81
Leukocyte mitochondrial DNA copy number in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.81
Childhood meningitis increases the risk for adult schizophrenia. World J Biol Psychiatry (2005) 0.81
Inhibition of platelet phospholipase A2 activity by catuaba extract suggests antiinflammatory properties. Phytother Res (2004) 0.81
Combining cognitive screening tests for the evaluation of mild cognitive impairment in the elderly. Clinics (Sao Paulo) (2009) 0.81
Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl) (2014) 0.81
BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry (2014) 0.81
Inhibition of cPLA2 and sPLA2 activities in primary cultures of rat cortical neurons by Centella asiatica water extract. Nat Prod Commun (2012) 0.81
Comparison between two tests of delayed recall for the diagnosis of dementia. Arq Neuropsiquiatr (2006) 0.80
Acute hormonal changes after IV citalopram and treatment response in OCD. Psychopharmacology (Berl) (2007) 0.80
Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids (2009) 0.79
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.79
Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2003) 0.79
Nogo CAA 3'UTR Insertion polymorphism is not associated with Schizophrenia nor with bipolar disorder. Schizophr Res (2005) 0.79
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) (2013) 0.79
Widespread electrical cortical dysfunction in schizophrenia. Schizophr Res (2004) 0.79
Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study. Psychopharmacology (Berl) (2005) 0.78
Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol (2015) 0.78
Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.78